CFB
HRTX icon

Cullen/Frost Bankers’s Heron Therapeutics HRTX Stock Holding History

Cullen/Frost Bankers’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,404
Closed -$2.79K – 1392
2024
Q3 		$2.79K Buy
1,404
+218
+18% +$521 ﹤0.01% 1083
2024
Q2 		$4.15K Buy
+1,186
New +$3.64K ﹤0.01% 982

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Cullen/Frost Bankers's HRTX Position: Q4 2024 in Review

Cullen/Frost Bankers sold out of Heron Therapeutics (HRTX) in Q4 2024, closing a stake of 1,404 shares — an estimated $2.79K sold.

Cullen/Frost Bankers first reported a position in HRTX in Q2 2024 and held it in 2 quarters. The position peaked at $4.15K in Q2 2024. 161 funds tracked by Wall St. Rank hold HRTX as of Q4 2024.

  • Cullen/Frost Bankers reported no remaining Heron Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Cullen/Frost Bankers sold 1,404 Heron Therapeutics shares in Q4 2024, an estimated $2.79K.
  • Cullen/Frost Bankers first reported a position in Heron Therapeutics in Q2 2024 and held it in 2 quarters.
  • Cullen/Frost Bankers's Heron Therapeutics position peaked at $4.15K in Q2 2024.
  • 161 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2024.

Based on Cullen/Frost Bankers's 13F filing for Q4 2024, filed 6 Feb 2025.